SCHEMBL1764908

SCHEMBL1764908

CCOC(=O)c1cc(-c2cccc(OCc3ccccc3)c2)n(-c2cccc(Cl)c2)n1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 10/20 0.59
MGLL Q99685 4/20 0.56
MDM2 Q00987 3/20 0.53
LMNA P02545 1/20 0.53
TP53 P04637 1/20 0.53
GABRA2 P47869 1/20 0.52
GABRB2 P47870 1/20 0.52
CA9 Q16790 1/20 0.52
BCL2 P10415 2/20 0.49
MCL1 Q07820 2/20 0.49
SLC16A3 O15427 1/20 0.49
SLC16A1 P53985 1/20 0.49
MCTS1 Q9ULC4 1/20 0.49
CHRNA7 P36544 1/20 0.48
PPP1CA P62136 1/20 0.47
BCHE P06276 1/20 0.47
LIPC P11150 1/20 0.47
ACHE P22303 1/20 0.47
LIPE Q05469 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765293 0.88 MDM2 (0.68) FAAHMDM2BCL2MCL1SLC16A3
SCHEMBL1764923 0.88 FAAH (0.56) FAAHMGLLLMNATP53GABRA2
SCHEMBL2193229 0.87 CA9 (0.65) FAAHMGLLMDM2LMNATP53
SCHEMBL1765033 0.87 FAAH (0.58) FAAHMGLLLMNATP53GABRA2
SCHEMBL1765509 0.86 CCKAR (0.60) FAAHMGLLLMNATP53GABRA2
SCHEMBL9893959 0.86 LMNA (0.66) FAAHMGLLMDM2LMNATP53
SCHEMBL1764934 0.86 LMNA (0.59) FAAHMGLLLMNATP53GABRA2
SCHEMBL1765420 0.86 FAAH (0.55) FAAHMGLLLMNATP53GABRA2
SCHEMBL3429446 0.85 SLC16A3 (0.48) FAAHMGLLMDM2LMNATP53
SCHEMBL1764907 0.84 FAAH (0.56) FAAHMGLLLMNATP53GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO FAAH 4725/4885MGLL 4676/4885MDM2 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.